Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades
Open Access
- 12 April 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (11) , 3765-3774
Abstract
Background: The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in the survival of lymphoma in an academic center in China.Methods: A total of 3840 consecutive patients with lymphoma diagnosed between 1996 and 2015 were reviewed. Eighty patients were excluded, and finally, 3760 patients were analyzed in this study. The cohort was divided into four groups according to calendar periods at diagnosis: 1996‐2000, 2001‐2005, 2006‐2010, and 2010‐2015. The overall survival (OS) rates among the four groups were compared.Results: The 5‐ and 10‐year OS for the whole cohort were 62% and 52%, respectively. The 5‐year OS of patient with classic Hodgkin lymphoma (cHL), mature B‐cell lymphoma (BCL), and peripheral T‐cell lymphoma (PTCL) were 79%, 63%, and 50%, respectively. Among mature BCL, the 5‐year OS was highest in follicular lymphoma (77.8%), followed by Burkitt lymphoma (76.5%), marginal zone lymphoma (74.1%), diffuse large B‐cell lymphoma (61.5%), small lymphocytic lymphoma/chronic lymphocytic leukemia (55.1%), and mantle cell lymphoma (44.3%). Among PTCL, the 5‐year OS was highest in ALK+anaplastic large cell lymphoma (79.0%), followed by ALK−anaplastic large cell lymphoma (63.1%), natural killer/T‐cell lymphoma (57.7%), angioimmunoblastic T‐cell lymphoma (34.9%, and peripheral T‐cell lymphoma not otherwise specified (27.6%). Significant improvement in the survival of lymphoma was observed, with the 5‐year OS increasing from 48% in 1996‐2000 to 65% in 2011‐2015 (P < .001). The 5‐year OS of patients with cHL, mature BCL, and PTCL changed from 55%, 49%, and 41% in 1996‐2000 to 79%, 65%, and 51% in 2011‐2015, respectively (P values were .014, .002, and .592, respectively).Conclusion: The survival of most types of lymphoma such as cHL and mature BCL, rather than PTCL, was improved significantly during the past two decades.Keywords
Funding Information
- Capital’s Funds for Health Improvement and Research (2018-1-2151)
This publication has 29 references indexed in Scilit:
- Mortality of lymphoma and myeloma in China, 2004–2017: an observational studyJournal of Hematology & Oncology, 2019
- Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registriesThe Lancet Global Health, 2018
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesThe Lancet, 2018
- Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell LymphomaJAMA Oncology, 2017
- 2016 US lymphoid malignancy statistics by World Health Organization subtypesCA: A Cancer Journal for Clinicians, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Demographic and other characteristics of nodal non-Hodgkin’s lymphoma managed in academic versus non-academic centersTherapeutic Advances in Hematology, 2015
- Health Care in ChinaChest, 2013
- Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional studyThe Lancet, 2012